Analisis Faktor Risiko Fenotipe Molekuler ER, PR dan HER2 pada Kanker Payudara di Surakarta
Keywords:
Kanker, Payudara, Fenotipe molekuler, Faktor risiko, HER2Abstract
Sekitar 18 juta penduduk dunia mengidap kanker di tahun 2018. Kanker payudara adalah kanker ganas penyebab utama kematian pada wanita. Fenotipe molekuler kanker ini merupakan pengkategorian berdasarkan ekspresi reseptor hormonal dan human epidermal growth factor receptor 2 .Di seluruh dunia, masih minim penelitian yang menguji faktor risiko dari 3 fenotipe molekuler tersebut. Pemahaman yang baik mengenai faktor risiko dapat membantu pengendalian penyakit secara lebih efektif. Menganalisis faktor risiko dari aspek biologis dan pekerjaan terhadap terjadinya tipe fenotipe molekuler ER,PR dan HER2 kanker payudara Invasif jenis No Special Type . Penelitian ini berdesain potong lintang, melibatkan 128 responden. Responden adalah penderita kanker payudara yang telah dianalisis fenotipe molekulernya dengan pemeriksaan imuno-histopatologi. Faktor-faktor risiko yang dianalisis meliputi: indeks masa tubuh, status klimakterium, lama pendidikan formal, pekerjaan dan status pernikahan. Analisis risiko dihitung dengan menggunakan penghitungan odd ratio. Pekerjaan non ibu rumah tangga berisiko untuk menderita kanker payudara berfenotipe molekuler HER2 positif (OR=2.417; 95%CI=1.173 – 4.981; p=0.017), pekerjaan non rumah tangga protektif untuk menderita kanker payudara berfenotipe triple negative (OR=0.077; 95%CI=0.010 – 0.602;p=0.015). Pekerjaan non ibu rumah tangga merupakan faktor risiko kanker payudara bertipe molekuler HER2+, dan faktor protektif untuk tipe triple negatif.
References
[2]. WHO. WHO report on cancer: setting priorities, investing wisely and providing care for all. World Health Organization. 2020.
[3]. Kurniati YP, Nafiah I. Fenotipe Estrogen Reseptor Berdasarkan Usia dan Pekerjaan Pada Kanker Payudara Invasif. In: The 10th University Research Colloqium 2019 Sekolah Tinggi Ilmu Kesehatan Muhammadiyah Gombong. 2019. p. 709–15.
[4]. Kemenkes RI. Profil Kesehatan Indonesia 2018 [Indonesia Health Profile 2018]. 2019. 207 p.
[5]. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
[6]. Khushalani JS, Qin J, Ekwueme DU, White A. Awareness of breast cancer risk related to a positive family history and alcohol consumption among women aged 15–44 years in United States. Prev Med Reports. 2020;17(December 2019):101029.
[7]. Moey S-F, Mardhiah Abdul Mutalib A, Che Mohamed N, Saidin N. The relationship of socio-demographic characteristics and knowledge of breast cancer on stage of behavioral adoption of breast self-examination. AIMS Public Heal. 2020;7(3):620–33.
[8]. Gupta R, Gupta S, Mehrotra R, Sodhani P. Risk factors of breast cancer and breast self-examination in early detection: Systematic review of awareness among Indian women in community and health care professionals. J Public Heal (United Kingdom). 2020;42(1):118–31.
[9]. Sari SE, Harahap WA, Saputra D. Pengaruh Faktor Risiko Terhadap Ekspresi Reseptor Estrogen Pada Penderita Kanker Payudara Di Kota Padang. J Kesehat Andalas. 2018;7(4):461.
[10]. Chen L, Li CI, Tang MC, Porter P, Hill DA, Wiggins CL, et al. Reproductive Factors and Risk of Luminal , Breast Cancer Among Multiethnic Women. Cancer Epidemiol Biomarkers Prev. 2016;25(9):1297–305.
[11]. Wang JM, Wang J, Zhao HG, Liu TT, Wang FY. Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China. Biomed Res Int. 2020;2020.
[12]. Anwar SL, Avanti WS, Nugroho AC, Choridah L, Dwianingsih EK, Harahap WA, et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: A hospital-based study in Indonesia. World J Surg Oncol. 2020;18(1):1–16.
[13]. Li Z, Wang K, Shi Y, Zhang X, Wen J. Incidence of second primary malignancy after breast cancer and related risk factors—Is breast-conserving surgery safe? A nested case–control study. Int J Cancer. 2020;146(2):352–62.
[14]. Walker RA, Kilpatrick R. Immunohistochemistry and Breast Cancer. In: Immunohistochemistry and Breast Cancer. 2003. p. 1–10.
[15]. Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofsta¨dter F, Gerstenhauer M, et al. 4-IHC classification of breast cancer subtypes in a large cohort. Breast Cancer Res Treat. 2015;
[16]. Ishikawa T, Ichikawa Y, Shimizu D, Sasaki T, Tanabe M, Chishima T, et al. The role of HER-2 in Breast Cancer. J Surg Sci. 2014;2(1):4–9.
[17]. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000;92(5):412–7.
[18]. Youn HJ, Han W. A review of the epidemiology of breast cancer in Asia: Focus on risk factors. Asian Pacific J Cancer Prev. 2020;21(4):867–80.
[19]. Park B, Lim SE, Ahn H, Yoon J, Choi YS. Heterogenous effect of risk factors on breast cancer across the breast density categories in a korean screening population. Cancers (Basel). 2020;12(6).
[20]. Arthur RS, Wang T, Xue X, Kamensky V, Rohan TE. Genetic factors, adherence to healthy lifestyle behavior, and risk of invasive breast cancer among women in the UK biobank. J Natl Cancer Inst. 2020;112(9):893–901.
[21]. Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, et al. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. JNCI J Natl Cancer Inst. 2020;113:329–37.
[22]. Pizzato M, Carioli G, Rosso S, Zanetti R, La Vecchia C. The impact of selected risk factors among breast cancer molecular subtypes: a case-only study. Breast Cancer Res Treat. 2020;184(1):213–20.
[23]. Rojas-Lima E, Gamboa-Loira B, Cebrián ME, Rothenberg SJ, López-Carrillo L. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women. Breast Cancer Res Treat. 2020;180(3):791–800.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Yuni Prastyo Kurniati, Yusuf Alam Romadhon
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
